| Name | Bcl w |
|---|---|
| Synonyms | Apoptosis regulator Bcl W; Apoptosis regulator BclW; BCL W; BCL2 like 2 protein; BCL2 like 2; BCL2L2; BCLW; Bcl 2 like 2 protein… |
| Name | biphenyl |
|---|---|
| CAS | 1,1′-biphenyl |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18806758 | Vogler M, Dinsdale D, Dyer MJ, Cohen GM: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009 Mar;16(3):360-7. Epub 2008 Sep 19. Antiapoptotic Bcl-2 family members may be divided into two subclasses, one comprising Bcl-2, Bcl-X (L) and Bcl-w and the other Mcl-1 and Bcl2A1. |
2(0,0,0,2) | Details |
| 19684859 | Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One. 2009 Aug 17;4(8):e6651. ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xl and Bcl-w, has demonstrated efficacy in several forms of leukemia, lymphoma as well as solid tumors. |
1(0,0,0,1) | Details |
| 20038611 | High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010 Mar;77(3):483-94. Epub 2009 Dec 28. ABT-737, a Bcl-2 homology domain 3 mimetic (for structure, see Nature 435:677-681, 2005) inhibits the prosurvival function of Bcl-2, Bcl-X (L), and Bcl-w. |
1(0,0,0,1) | Details |
| 19494271 | Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, Mathieu S, Grinnell C, Erickson J, Rosenberg SH, Schwartz AJ, Hugunin M, Tarcsa E, Elmore SW, McRae B, Murtaza A, Wang LC, Ghayur T: The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009 Jun 15;182(12):7482-9. ABT-737, which was originally developed for oncology, is a potent inhibitor of Bcl-2, Bcl-x (L), and Bcl-w protein function. |
1(0,0,0,1) | Details |
| 18807035 | Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A: Immunosensitization with a Bcl-2 small molecule inhibitor. . Cancer Immunol Immunother. 2009 May;58(5):699-708. Epub 2008 Sep 20. ABT-737, a small molecule inhibitor of the antiapoptotic proteins Bcl-2, Bcl-w and Bcl-x (L), was tested for the ability to increase antitumor immune responses in two tumor immunotherapy animal models. |
1(0,0,0,1) | Details |
| 18987671 | Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG: BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009 Apr;129(4):964-71. Epub 2008 Nov 6. The BH3 mimetic ABT-737 is a potent small molecule inhibitor of the anti-apoptotic proteins Bcl-2/Bcl-X (L)/Bcl-w. |
1(0,0,0,1) | Details |
| 19060244 | Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R: Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood. 2009 Feb 12;113(7):1522-5. Epub 2008 Dec 5. ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-X (L), and Bcl-W, induced apoptosis preferentially in JAK2V617F-high PV erythroid precursors as compared with JAK2V617F-low or normal erythroblasts. |
1(0,0,0,1) | Details |
| 18591385 | Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008 Oct 1;112(7):2906-16. Epub 2008 Jun 30. ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X (L), and Bcl-w. |
1(0,0,0,1) | Details |
| 18767026 | Azmi AS, Mohammad RM: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 2009 Jan;218(1):13-21. Cancer cells that are resistant to various anti-cancer drugs and treatment regimen are found to over express these Bcl-2 proteins such as Bcl-2, Bcl-X (L), Mcl-1, Bcl-w, and A1/Bfl1. |
1(0,0,0,1) | Details |
| 19060243 | Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW: Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009 Feb 26;113(9):1982-91. Epub 2008 Dec 5. However, in contrast to the reported binding specificity data, Emu-myc/Bcl-w lymphomas were insensitive to ABT-737 used alone or in combination with HDACi, indicating that the regulatory activity of ABT-737 is restricted to Bcl-2 and Bcl-X (L). |
1(0,0,0,1) | Details |
| 19228717 | Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009 Feb 15;15(4):1126-32. One pathway being targeted for antineoplastic therapy is the anti-apoptotic B-cell lymphoma-2 (Bcl-2) family of proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that bind to and inactivate BH3-domain pro-apoptotic proteins. |
2(0,0,0,2) | Details |
| 19737541 | Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM: ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol. 2010 Feb 1;79(3):339-49. Epub 2009 Sep 6. The small molecule inhibitor, ABT-737, which binds to and inhibits Bcl-2, Bcl-xL and Bcl-w, was used in combination with doxorubicin/AN-9 treatments to overcome resistance to doxorubicin-DNA adducts in Bcl-2 overexpressing HL-60 cells (HL-60/Bcl-2). |
1(0,0,0,1) | Details |